Across TCGA pan-cancer cohorts, RILP Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RILP data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher RILP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RILP expression acts as an unfavorable survival marker.
READ and LUAD are the cancer types where RILP Mutation most reproducibly stratifies survival.